Healthcare Professionals

A woman’s lifetime risk of dying from a hip fracture is similar to her risk of dying from breast cancer1

Up to 24% of patients over 50 die from complications from a hip fracture in the first year following the fracture2

Approximately 1 in 2 women over age 50 will have an osteoporosis-related fracture in their remaining lifetime.3

You know the risks are real. Osteoporosis can change a woman’s world.

With BINOSTO® you can strengthen her world with the proven power of alendronate in a buffered effervescent solution. Now, you can give your patients:

Proven fracture-risk reduction at the hip and spine

  • Bioequivalent to 70 mg Fosamax® (once weekly)4
  • More than 14 million prescriptions were written for alendronate in the 12-month period ending June 2012*

Once-weekly therapy that’s easy to take

  • Dissolves into a strawberry-flavored, buffered solution
  • Ideal for patients with difficulty swallowing tablets

Fosamax is a registered trademark of Merck & Co., Inc.

*Wolters Kluwer Source PHAST Prescription Data. Accessed August 2012.

  • 1. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white menopausal women. Arch Intern Med. 1989 Nov;149(11):2445-8.
  • 2. Osteoporosis facts and statistics [Internet]. International Osteoporosis Foundation. Accessed 23 May 2012. Available from:
  • 3. US Preventive Services Task Force. Screening for osteoporosis: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2011 Mar 1;154(5):356-64. Epub 2011 Jan 17.
  • 4. BINOSTO prescribing information. Mission Pharmacal Company

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Click me, it will be preserved!

If you try to open a new ColorBox while it is already open, it will update itself with the new content.

Updating Content Example:
Click here to load new content